

Case IPR2024-00874
U.S. Patent No. 11,697,028

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

BIOFRONTERA INC., BIOFRONTERA BIOSCIENCE GMBH,
BIOFRONTERA PHARMA GMBH, AND BIOFRONTERA AG
Petitioner

v.

DUSA PHARMACEUTICALS, INC.
Patent Owner

Case IPR2024-00874

U.S. Patent No. 11,697,028

UPDATED MANDATORY NOTICES FOR PATENT OWNER

Mail Stop Patent Board
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Patent Owner Sun Pharmaceutical Industries, Inc. (“Sun” or “Patent Owner”)¹

hereby files its updated mandatory notices.

I. REAL PARTY-IN-INTEREST (37 C.F.R. § 42.8(b)(1))

No change.

II. RELATED MATTERS (37 C.F.R. § 42.8(b)(2))

A. Judicial Matters

The following matters may affect or be affected by this proceeding: *In Re Certain Photodynamic Therapy Systems, Components Thereof, And Pharmaceutical Products Used In Combination With The Same*, Investigation No. 337-TA-1411 (U.S. International Trade Commission); and *Sun Pharmaceutical Industries, Inc. v. Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, Biofrontera AG, and Biofrontera Inc.*, Civil Action No. 1:24-cv-11637 (D. Mass).

B. Administrative Matters.

No change.

III. DESIGNATION OF LEAD AND BACK-UP COUNSEL (37 C.F.R. § 42.8(b)(3))

No change.

IV. SERVICE INFORMATION (37 C.F.R. § 42.8(b)(4))

No change.

¹ DUSA Pharmaceuticals, Inc. merged with Sun Pharmaceutical Industries, Inc. effective March 31, 2024, with Sun Pharmaceutical Industries, Inc. remaining as the surviving corporation.

Case IPR2024-00874
U.S. Patent No. 11,697,028

Dated: August 6, 2024

Respectfully submitted,

/s/ Gabrielle E. Higgins

Gabrielle E. Higgins (Reg. No. 38,916)

ghiggins@desmaraisllp.com

DESMARAIS LLP

101 California Street, Suite 3000

San Francisco, CA 94111

415-573-1902 (telephone)

415-573-1901 (facsimile)

*Lead Counsel for Patent Owner,
Sun Pharmaceutical Industries, Inc.*

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), the undersigned certifies that a complete copy of the foregoing was caused to be served on counsel of record for the Petitioner by filing this document through PTACTS and by sending this document via electronic mail to the following addresses:

George B. Davis (Reg. No. 68,205)
MCGUIREWOODS LLP
Gateway Plaza
800 East Canal Street
Richmond, VA 23219
Tel.: (804) 775-1129
Fax.: (804) 775-2016
gdavis@mcguirewoods.com

Tyler T. VanHoutan (Reg. No. 54,506)
MCGUIREWOODS LLP
845 Texas Ave.
Suite 2400
Houston, TX 77002
Tel.: (713) 571-9191
Fax.: (713) 571-9652
tvanhoutan@mcguirewoods.com

Dated: August 6, 2024

Respectfully submitted,

/s/ Gabrielle E. Higgins

Gabrielle E. Higgins (Reg. No. 38,916)
ghiggins@desmaraisllp.com
DESMARAIS LLP
101 California Street, Suite 3000
San Francisco, CA 94111
415-573-1902 (telephone)
415-573-1901 (facsimile)

*Lead Counsel for Patent Owner,
Sun Pharmaceutical Industries, Inc.*